Patients
Open a record to continue, or start a new patient.
| Patient | Age / Sex | Latest LDL-C | Record | Risk | Next step | Reimbursement | |
|---|---|---|---|---|---|---|---|
|
Hans Brunner
PT-0001
|
71 / Male | 2.1 mmol/L 20.08.2026 | Complete | Very High | Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab) | Eligible | Open Edit |
|
Marie Bochud
PT-0002
|
64 / Female | 3.4 mmol/L 28.08.2026 | Complete | Very High | Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab) | Eligible | Open Edit |
|
Peter Zimmermann
PT-0003
|
77 / Male | 3.2 mmol/L 12.08.2026 | Complete | High | Escalate to a high-intensity statin | Not applicable | Open Edit |
|
Ursula Meier
PT-0004
|
68 / Female | 2.4 mmol/L 01.09.2026 | Complete | High | Escalate to a high-intensity statin | Not applicable | Open Edit |
|
Claudia Steiner
PT-0006
|
55 / Female | 3.9 mmol/L 25.08.2026 | Complete | Moderate | Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab) | Not eligible | Open Edit |
|
Jean-Pierre Nicolet
PT-0007
|
73 / Male | 1.6 mmol/L 18.08.2026 | Complete | Very High | Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab) | Eligible | Open Edit |
|
Verena Wyss
PT-0008
|
59 / Female | 3.1 mmol/L 30.08.2026 | Complete | Very High | Escalate to a high-intensity statin | Not applicable | Open Edit |
|
Andreas Baumann
PT-0009
|
41 / Male | 3.3 mmol/L 05.09.2026 | Complete | Low | Initiate high-intensity statin | Not applicable | Open Edit |
|
Chantal Descloux
PT-0010
|
67 / Female | 1.9 mmol/L 22.08.2026 | Complete | Very High | Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab) | Eligible | Open Edit |
|
Umberto Race
PT-0011
|
61 / Male | 3.4 mmol/L 09.09.2026 | Complete | Very High | Add ezetimibe to the current statin therapy | Not applicable | Open Edit |
|
Celine Kalbermatten-Saugy
PT-0012
|
50 / Female | — | 2 / 4 steps | — | — | — | Open Edit |
|
Gabriel Blanc
PT-0014
|
63 / Male | — | 2 / 4 steps | — | — | — | Open Edit |
|
m coralie
PT-0015
|
47 / Female | 3.6 mmol/L 10.09.2026 | Complete | Low | Initiate high-intensity statin | Not applicable | Open Edit |
|
Perroud G
PT-0016
|
67 / Male | — | 1 / 4 steps | — | — | — | Open Edit |
|
Perroud G
PT-0017
|
67 / Male | 1.8 mmol/L 10.09.2026 | Complete | Moderate | At target — continue current therapy and monitor | Not applicable | Open Edit |
|
Test Test 2
PT-0018
|
76 / Male | 2 mmol/L 18.09.2026 | Complete | Very High | Add ezetimibe to the current statin therapy | Not applicable | Open Edit |
|
Test Test
PT-0019
|
29 / Male | — | 2 / 4 steps | — | — | — | Open Edit |
|
micharl Enry
PT-0020
|
36 / Male | — | 2 / 4 steps | — | — | — | Open Edit |
|
micharel erbsfa
PT-0021
|
36 / Female | 14 mmol/L 16.09.2026 | Complete | Very High | Initiate high-intensity statin | Not applicable | Open Edit |
|
Steve Jacot-Descombes
PT-0022
|
60 / Male | — | 2 / 4 steps | — | — | — | Open Edit |
Demo patients are synthetic and can be edited freely — use “Reset demo values” inside a record to restore them.